Mark Mahaney, Evercore ISI head of internet research, joins 'Closing Bell' to discuss the markets, Meta's historic winning ...

Wall Street investment bank Evercore ISI (EVR) is pounding the table on Nvidia (NVDA) stock ahead of the chipmaker’s upcoming ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by Evercore ISI from an “in-line” rating to an “outperform” ...

Teradata (NYSE:TDC – Free Report) had its target price cut by Evercore ISI from $37.00 to $32.00 in a research report report ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) ...

Evercore ISI analyst Kirk Materne maintained a Hold rating on Tyler Technologies (TYL – Research Report) yesterday and set a price target of ...

Fears that DeepSeek may be moving AI workloads from Nvidia's GPUs to Application-Specific Integrated Circuits combined with possible delays in the Blackwell chip release have caused lags in Nvidia ...

Evercore ISI lifted Juniper Networks (NYSE:JNPR) stock to Outperform from In-Line on Tuesday while maintaining a $40 price target.

Rich Ross, head of technical analysis at Evercore ISI, said that a breakout to an all-time high in the S&P 500 ( SP500 ), ( ...

In the lead-up to Nvidia Inc.’s NVDA forthcoming earnings report after market close on Feb.26, Evercore ISI suggests that it is a good buying opportunity amid strong fundamentals. What Happened: In a ...

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.